Analysis and Commentary STEVEN GROSSMAN 2/22/19 Analysis and Commentary STEVEN GROSSMAN 2/22/19 Four More Qs and Four More As Read More Analysis and Commentary STEVEN GROSSMAN 2/15/19 Analysis and Commentary STEVEN GROSSMAN 2/15/19 Some Issues Continue to Raise Questions Read More STEVEN GROSSMAN 2/15/19 STEVEN GROSSMAN 2/15/19 Long Wait Is Over. FY 19 FDA Funding Will Be Set When the President Signs the Appropriations Bill Read More Analysis and Commentary STEVEN GROSSMAN 2/8/19 Analysis and Commentary STEVEN GROSSMAN 2/8/19 The Questions -- and the Answers -- Continue! Read More Analysis and Commentary STEVEN GROSSMAN 2/1/19 Analysis and Commentary STEVEN GROSSMAN 2/1/19 Members' Questions Are Still Flowing In Read More Advocacy at a Glance STEVEN GROSSMAN 2/1/19 Advocacy at a Glance STEVEN GROSSMAN 2/1/19 February 15 Is the New Deadline; Negotiations Begin Read More Analysis and Commentary STEVEN GROSSMAN 1/26/19 Analysis and Commentary STEVEN GROSSMAN 1/26/19 Shutdown- and BA-Related Q&As Continued Read More Advocacy at a Glance STEVEN GROSSMAN 1/26/19 Advocacy at a Glance STEVEN GROSSMAN 1/26/19 Possible Temporary End to Shutdown Announced. Read More Advocacy at a Glance STEVEN GROSSMAN 1/11/19 Advocacy at a Glance STEVEN GROSSMAN 1/11/19 Deteriorating Situation at Shut-Down FDA, Despite Commissioner Gottlieb’s Best Efforts Read More Analysis and Commentary STEVEN GROSSMAN 1/4/19 Analysis and Commentary STEVEN GROSSMAN 1/4/19 Can the Alliance Help to End the Shutdown? No and Yes! Read More Advocacy at a Glance STEVEN GROSSMAN 12/21/18 Advocacy at a Glance STEVEN GROSSMAN 12/21/18 Barring a Last-Minute Deal, A Partial FDA Shutdown is Likely Read More Advocacy at a Glance STEVEN GROSSMAN 12/10/18 Advocacy at a Glance STEVEN GROSSMAN 12/10/18 Two-Week CR Extension: Can It End the Impasse? Read More Analysis and Commentary STEVEN GROSSMAN 11/30/18 Analysis and Commentary STEVEN GROSSMAN 11/30/18 "The Best of Times" ... "The Worst of Times" Read More Advocacy at a Glance STEVEN GROSSMAN 11/30/18 Advocacy at a Glance STEVEN GROSSMAN 11/30/18 A Full Year Continuing Resolution: The Biggest Threat to FDA’s FY19 Funding Read More Advocacy at a Glance STEVEN GROSSMAN 11/20/18 Advocacy at a Glance STEVEN GROSSMAN 11/20/18 Special Thanksgiving Message Read More Advocacy at a Glance STEVEN GROSSMAN 11/9/18 Advocacy at a Glance STEVEN GROSSMAN 11/9/18 Will Congress Complete Appropriations in the Post-Recess Session or Further Extend the CR? Read More Advocacy at a Glance STEVEN GROSSMAN 11/2/18 Advocacy at a Glance STEVEN GROSSMAN 11/2/18 Will Congress Complete Appropriations in the Post-Recess Session? Read More Analysis and Commentary STEVEN GROSSMAN 10/5/18 Analysis and Commentary STEVEN GROSSMAN 10/5/18 Will This Year’s Lame Duck Conduct “Business as Usual”? Read More Advocacy at a Glance STEVEN GROSSMAN 10/5/18 Advocacy at a Glance STEVEN GROSSMAN 10/5/18 October 1 Came and Went: CR Covers FDA Until December 7 Read More Advocacy at a Glance STEVEN GROSSMAN 9/28/18 Advocacy at a Glance STEVEN GROSSMAN 9/28/18 FDA Appropriations in Limbo and more Read More Older Posts
Analysis and Commentary STEVEN GROSSMAN 2/22/19 Analysis and Commentary STEVEN GROSSMAN 2/22/19 Four More Qs and Four More As Read More
Analysis and Commentary STEVEN GROSSMAN 2/15/19 Analysis and Commentary STEVEN GROSSMAN 2/15/19 Some Issues Continue to Raise Questions Read More
STEVEN GROSSMAN 2/15/19 STEVEN GROSSMAN 2/15/19 Long Wait Is Over. FY 19 FDA Funding Will Be Set When the President Signs the Appropriations Bill Read More
Analysis and Commentary STEVEN GROSSMAN 2/8/19 Analysis and Commentary STEVEN GROSSMAN 2/8/19 The Questions -- and the Answers -- Continue! Read More
Analysis and Commentary STEVEN GROSSMAN 2/1/19 Analysis and Commentary STEVEN GROSSMAN 2/1/19 Members' Questions Are Still Flowing In Read More
Advocacy at a Glance STEVEN GROSSMAN 2/1/19 Advocacy at a Glance STEVEN GROSSMAN 2/1/19 February 15 Is the New Deadline; Negotiations Begin Read More
Analysis and Commentary STEVEN GROSSMAN 1/26/19 Analysis and Commentary STEVEN GROSSMAN 1/26/19 Shutdown- and BA-Related Q&As Continued Read More
Advocacy at a Glance STEVEN GROSSMAN 1/26/19 Advocacy at a Glance STEVEN GROSSMAN 1/26/19 Possible Temporary End to Shutdown Announced. Read More
Advocacy at a Glance STEVEN GROSSMAN 1/11/19 Advocacy at a Glance STEVEN GROSSMAN 1/11/19 Deteriorating Situation at Shut-Down FDA, Despite Commissioner Gottlieb’s Best Efforts Read More
Analysis and Commentary STEVEN GROSSMAN 1/4/19 Analysis and Commentary STEVEN GROSSMAN 1/4/19 Can the Alliance Help to End the Shutdown? No and Yes! Read More
Advocacy at a Glance STEVEN GROSSMAN 12/21/18 Advocacy at a Glance STEVEN GROSSMAN 12/21/18 Barring a Last-Minute Deal, A Partial FDA Shutdown is Likely Read More
Advocacy at a Glance STEVEN GROSSMAN 12/10/18 Advocacy at a Glance STEVEN GROSSMAN 12/10/18 Two-Week CR Extension: Can It End the Impasse? Read More
Analysis and Commentary STEVEN GROSSMAN 11/30/18 Analysis and Commentary STEVEN GROSSMAN 11/30/18 "The Best of Times" ... "The Worst of Times" Read More
Advocacy at a Glance STEVEN GROSSMAN 11/30/18 Advocacy at a Glance STEVEN GROSSMAN 11/30/18 A Full Year Continuing Resolution: The Biggest Threat to FDA’s FY19 Funding Read More
Advocacy at a Glance STEVEN GROSSMAN 11/20/18 Advocacy at a Glance STEVEN GROSSMAN 11/20/18 Special Thanksgiving Message Read More
Advocacy at a Glance STEVEN GROSSMAN 11/9/18 Advocacy at a Glance STEVEN GROSSMAN 11/9/18 Will Congress Complete Appropriations in the Post-Recess Session or Further Extend the CR? Read More
Advocacy at a Glance STEVEN GROSSMAN 11/2/18 Advocacy at a Glance STEVEN GROSSMAN 11/2/18 Will Congress Complete Appropriations in the Post-Recess Session? Read More
Analysis and Commentary STEVEN GROSSMAN 10/5/18 Analysis and Commentary STEVEN GROSSMAN 10/5/18 Will This Year’s Lame Duck Conduct “Business as Usual”? Read More
Advocacy at a Glance STEVEN GROSSMAN 10/5/18 Advocacy at a Glance STEVEN GROSSMAN 10/5/18 October 1 Came and Went: CR Covers FDA Until December 7 Read More
Advocacy at a Glance STEVEN GROSSMAN 9/28/18 Advocacy at a Glance STEVEN GROSSMAN 9/28/18 FDA Appropriations in Limbo and more Read More
